- Home
- OBIO vs PALI Comparison
OBIO vs PALI Comparison
Compare OBIO & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | PALI |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 240.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OBIO | PALI |
|---|---|---|
| Price | $3.95 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $14.25 | ★ $15.00 |
| AVG Volume (30 Days) | 219.1K | ★ 5.2M |
| Earning Date | 11-10-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,818,000.00 | N/A |
| Revenue This Year | $36.66 | N/A |
| Revenue Next Year | $2.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $0.53 |
| 52 Week High | $6.02 | $2.64 |
Technical Indicators
Market Signals| Indicator | OBIO | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 39.92 |
| Support Level | $3.46 | $1.48 |
| Resistance Level | $4.24 | $1.68 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 45.70 | 13.73 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.